Pfizer Opposes Creation of Federal Lipitor Lawsuit Litigation, Over 100 Cases Filed

Published on November 14, 2013 by Sandy Liebhard

Text-Size:A A A+


Lipitor lawsuit claims alleging new-onset Type 2 diabetes from the cholesterol medication are continuing to rise in the U.S., but the drug manufacturer is opposing the creation of a multidistrict litigation, according to court documents.

A Response filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) on November 1st indicates that Pfizer, Inc. is arguing that the creation of a multidistrict litigation would delay its progress, to which Plaintiffs have countered that a single proceeding would keep lawsuits moving forward and properly allocate the resources of the court.

According to the Pfizer-issued document, over 100 Lipitor diabetes claims have been filed in various federal jurisdictions throughout the U.S. Plaintiffs involved in these cases petitioned the JPML on the creation of a multidistrict litigation in October for the second time that year, and proposed the U.S. District Court, District of South Carolina as an appropriate location. Earlier in 2013, the Panel denied a request brought by different Lipitor claimants on the grounds that not enough cases had been filed in the U.S. At the time, no more than two dozen lawsuits were pending in U.S. courts, which was not enough to warrant a consolidated proceeding, they said. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2459 (JPML))

Lipitor Lawsuit Claims Grow after FDA Order to Adjust Cholesterol Drug Labeling

Since the U.S. Food and Drug Administration (FDA) ordered Pfizer to adjust Lipitor’s labeling in February 2012 to include the risk for new-onset diabetes, concerns about the statin have increased steadily. The agency’s mandate was prompted by the findings of a study in JAMA: Internal Medicine that found post-menopausal women treated with the statin at an increased risk for the disease.

Most recently, a Lipitor lawsuit was filed in West Virginia federal court by a woman who began taking the cholesterol-lowering statin in 2005, and was diagnosed with Type 2 diabetes in 2009. Her claim against Pfizer, Inc. alleges the company’s failure to properly warn doctors and patients about the risk for this disease to develop after use of its product. Her Lipitor diabetes complications were experienced before Pfizer adjusted the drug’s labeling, according to documents filed on October 28th.

 Contact an Attorney for More about Lipitor Lawsuits

If you developed new-onset Type 2 diabetes after taking Lipitor, you may be entitled to file a lawsuit seeking compensation for your injuries. Call the Firm directly to learn more about the legal process of pursuing a claim at .